
Robert Sebra, PhD
About Me
Robert Sebra, PhD, is a Professor in the Department of Genetics and Genomic Sciences, Director of The Center for Advanced Genomics Technology, and Director of Technology Development for the Genomics Core Facility at the Icahn School of Medicine at Mount Sinai. He is a faculty member of the Icahn Genomics Institute. His research lab centers on creating and applying bulk and single cell molecular methods to generate highly resolved data using genomics technology for variant discovery and annotation. This research integrates single molecular and cellular genomics data with assays to assess chromatin accessibility, proteomics, and epigenetics data to decipher factors of pathogenesis versus normal cellular functions. Determining which cellular niches and mechanisms in complex primary tissues drive disease or resilience facilitates translation of functional genomics data using model systems for screening possible downstream regenerative and therapeutic potential using high throughput methods.
Ongoing research interests include:
- Developing novel molecular methods and genome sequencing technologies
- Advancing high-throughput functional genomics
- Exploring whole genome and repeat content characterization for disease association
- Analyzing surveillance and genomic characterization of pathogen transmission
- Using genomics to temporally characterize development and pathogenesis
- Translating genomic data in various oncologic diseases including gynecologic and breast cancers
Language
English
Position
PROFESSOR | Genetics and Genomic Sciences
Research Topics
Biomedical Informatics, Cancer, Cancer Genetics, Epigenetics, Gene Expressions, Genetics, Infectious Disease, Molecular Biology, RNA, RNA Splicing & Processing, Stem Cells, Technology & Innovation, Translational Research
Multi-Disciplinary Training Areas
Genetics and Genomic Sciences [GGS]
Publications
Selected Publications
- Author Correction: A streamlined base editor engineering strategy to reduce bystander editing (Nature Communications, (2025), 16, 1, (8115), 10.1038/s41467-025-63609-6). Izabella Valdez, Ian O’Connor, Divesh Patel, Katherine Gierer, Jan Harrington, Ethan Ellis, Stephen A. Caponetti, Robert P. Sebra, Hillary C. Valley, Kevin Coote, Martin Mense, Samuele G. Marro, Tingting Jiang. Nature Communications
- Intracoronary Imaging and Transcriptomic Characteristics Before and After Maximum Lipid-Lowering Therapy: YELLOW-III Study of Evolocumab and Maximum Statin Therapy in Chronic Coronary Disease. Annapoorna S. Kini, Yuliya Vengrenyuk, Jia Jia Liu, Keisuke Yasumura, Pruthvi C. Revaiah, Aishwaria Mandava, Hardik Shah, Joseph M. Sweeny, Sahil Khera, Vishal Kapur, Parasuram Melarcode-Krishnamoorthy, Amit Hooda, Shingo Minatoguchi, Nimisha Baruah, Derek A. Pineda, Vivian Chen, Ethan Ellis, Aana Hahn, Prakash Krishnan, Usman Baber, Pedro R. Moreno, Roxana Mehran, Robert Sebra, Eric Boerwinkle, Xiaobo Zhou, Jagat Narula, Samin K. Sharma. JACC: Cardiovascular Imaging
- Correction: Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer (Clin Cancer Res (2017), 23, (1552-1563), 10.1158/1078-0432.CCR-16-1333). Ying Chen, Sandra Catalina Camacho, Thomas R. Silvers, Albiruni R.A. Razak, Nashat Y. Gabrail, John F. Gerecitano, Eva Kalir, Elena Pereira, Brad R. Evans, Susan J. Ramus, Fei Huang, Nolan Priedigkeit, Estefania Rodriguez, Michael Donovan, Faisal Khan, Tamara Kalir, Robert Sebra, Andrew Uzilov, Rong Chen, Rileen Sinha, Richard Halpert, Jean Noel Billaud, Sharon Shacham, Dilara McCauley, Yosef Landesman, Tami Rashal, Michael Kauffman, Mansoor R. Mirza, Morten Mau-Sørensen, Peter Dottino, John A. Martignetti. Clinical Cancer Research
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Sebra during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Equity
(Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)- Panacent Bio
Founder/Co-Founder/Partner
- Panacent Bio
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.